Ipamorelin
Ipamorelin is a growth-hormone secretagogue used in performance and longevity settings, but current FDA treatment keeps it out of normal compounding channels.
Current status
Restricted
Growth hormone support, with current federal compounding constraints still in play.
FDA category
Category 2
Can pharmacies compound this?
No
Reclassification expected?
Yes
Still discussed as a candidate for future review, particularly in 503B conversations.
Primary Use
Growth hormone support
Regulatory Timeline
Mar 15, 2023
FDA peptide compounding scrutiny intensified across 503A and 503B channels.
Sep 29, 2023
Current status signal recorded: 503B and clinic availability contracted after Category 2 treatment..
Feb 27, 2026
Political pressure and market expectations increased around a future peptide reclassification review.
Get notified...
Get notified when Ipamorelin status changes
State-specific notes
Ohio
Office-use sourcing is especially limited.